Clinical trial NCT03278132: Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine
Official title: A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hand, Foot and Mouth Disease
Keywords: Inactivated Enterovirus Type 71 (EV71) Vaccine
Safety
Immunogenicity
Infant
Lead sponsor: Sinovac Biotech Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: Zhejiang Provincial Center for Disease Control and Prevention
name: Shangyu District Center for Disease Control and Prevention
First posted: 2017-09-11
Enrollment: 120
Sex: ALL
Minimum age (years): 6
Maximum age (years): 35
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination

Detailed description: This study is an open-labelled, single-centered, stratified-randomized, phase IV clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine (developed by Sinovac Biotech Co., Ltd.) in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different times after vaccination. The enrolled subjects in this study receive two doses of EV71 vaccine with 1-month interval between doses. To evaluate safety of the vaccine, subjects will be observed for 30 days after the injection for the potential adverse events. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the neutralizing antibody detection prior to vaccination, 10/20/30 days after the 1st dose and 30 days after the 2nd dose vaccination. All subjects will receive blood sampling for three times. Subjects will be randomly assigned to receive blood sampling at 10/20/30 days after 1st dose injection, with a ratio of 1: 1: 1.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers aged 6-35 months old
* Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study
* Proven legal identity

Exclusion Criteria:

For subjects with any of the following conditions, vaccination should not be administrated:

* History of hand foot and mouth disease
* Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, pain, etc
* Severe chronic diseases
* Thrombocytopenia or hemorrhagic disease
* Immunodeficiency disease or receipt of immunosuppressant treatment
* Uncontrolled epilepsy or progressive neurological disorders(e.g. Guillain-Barre syndrome)
* Acute disease or acute stage of chronic disease prior to the study entry
* History of thyroidectomy, thyroid disease within 12 months prior to the study entry
* Asplenia or functional asplenia
* Axillary temperature \>37.0 ℃
* Any other factor that suggesting the volunteer is unsuitable for this study based on the judgment of investigators

Exclusion Criteria of the Second Injection:

* Subjects with any of the following conditions are forbidden to continue the 2nd dose of vaccination:

  1. Any serious adverse event that has a causal relationship with the investigated vaccine
  2. Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination
  3. Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
  4. Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions)determined by the investigators
* For subjects suffering from acute disease or acute stage of chronic disease , whether to continue vaccination depends on themselves
* Subjects with the following conditions may receive vaccination in delayed time or withdraw from the study depending on the judgment of investigator

  1. Acute disease (moderate or severe disease with or without fever) in case of vaccination
  2. Axillary temperature \> 37.0 °C

Primary outcomes:
measure: The seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination
timeFrame: 30 days
Secondary outcomes:
measure: The seroconversion rate of EV71 neutralizing antibody 10, 20 and 30 days after the first dose vaccination
timeFrame: 10,20,and 30 days
measure: The seropositive rate of EV71 neutralizing antibody 10, 20, 30, and 60 days after the first dose vaccination
timeFrame: 10, 20,30,and 60 days
measure: GMT and GMT increase fold of EV71 neutralizing antibody 10,20,30,and 60 days after the first dose vaccination
timeFrame: 10,20，30，and 60 days
measure: Incidence of unsolicited local or systemic adverse events within 3 days after each dose
timeFrame: 3 days
measure: Incidence of unsolicited adverse events within 30 days after each dose
timeFrame: 30 days
measure: Incidence of the serious adverse events within 60 days after the first dose vaccination
timeFrame: 60 days
Other outcomes:
Locations:
city: Shaoxing
country: China
facility: Shangyu District Center for Disease Control and Prevention
state: Zhejiang
Study officials:
affiliation: Zhejiang Provincial Center for Disease Control and Prevention
name: Huakun Lv
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang S, Zeng J, Zhang X, Gan Z, Fan J, Chen Y, Liang Z, Hu X, Zeng G, Lv H. Short-term dynamic changes in neutralizing antibodies against enterovirus 71 after vaccination. Hum Vaccin Immunother. 2020 Jul 2;16(7):1595-1601. doi: 10.1080/21645515.2020.1711678. Epub 2020 Jan 24.